Valuation: Genflow Biosciences plc

Market Cap 9.35M 12.42M 11.19M 10.34M 17.68M 1.16B 18.12M 124M 49.38M 624M 46.59M 45.6M 1.98B P/E 2024
-3.64x
P/E 2025 -5.57x
Enterprise Value 9.23M 12.27M 11.06M 10.21M 17.47M 1.15B 17.9M 122M 48.79M 616M 46.04M 45.06M 1.96B EV / Sales 2024
17,954,064x
EV / Sales 2025 15,400,847x
Free-Float
53.53%
Yield 2024 *
-
Yield 2025 -
1 day-1.74%
1 week-11.16%
Current month-11.16%
1 month-9.93%
3 months-20.52%
6 months-26.30%
Current year-12.36%
1 week 1.6
Extreme 1.6
1.85
1 month 1.6
Extreme 1.6
1.94
Current year 1.21
Extreme 1.211
3.12
1 year 1.21
Extreme 1.211
3.12
3 years 0.55
Extreme 0.55
3.41
5 years 0.55
Extreme 0.55
13.5
10 years 0.55
Extreme 0.55
13.5
Manager TitleAgeSince
Chief Executive Officer 68 2019-12-31
Director TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member 68 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/25 Buy

Founder

40,000,000 11.4382%
3/28/25 Buy

Founder

2,100,000 0.6005%
8/15/22 Buy

Founder

106,000 0.0362%
Change 5-day change 1-year change 3-year change Capi.($)
-1.74%-11.16%-18.94%+1.33% 12.42M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.58%+9.02%+14.29%+93.26% 60.74B
+0.35%-0.89%+20.16%+98.57% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-1.33%-3.63%+78.22%+55.14% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average +0.04%+0.57%+37.24%+174.41% 41B
Weighted average by Cap. +0.17%+1.64%+43.64%+168.42%

Financials

2024 2025
Net sales 0.32 0.43 0.38 0.35 0.61 39.93 0.62 4.25 1.69 21.38 1.6 1.56 68.05 0.59 0.78 0.7 0.65 1.11 72.96 1.14 7.76 3.09 39.08 2.92 2.86 124.36
Net income -1.59M -2.11M -1.9M -1.76M -3M -198M -3.08M -21.04M -8.39M -106M -7.91M -7.75M -337M -1.42M -1.88M -1.7M -1.57M -2.68M -177M -2.75M -18.79M -7.49M -94.59M -7.07M -6.92M -301M
Net Debt -279K -370K -334K -308K -527K -34.72M -540K -3.69M -1.47M -18.6M -1.39M -1.36M -59.18M -112K -149K -134K -124K -211K -13.93M -217K -1.48M -591K -7.46M -557K -546K -23.74M
Projected Income Statement - Annual - Genflow Biosciences plc
Logo Genflow Biosciences plc
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Employees
5
Date Price Change Volume
26-11-12 GBX 1.621 -1.74% 218,169
26-11-11 GBX 1.650 +1.54% 432,505
26-11-10 GBX 1.625 -6.34% 669,991
26-11-09 GBX 1.735 +0.58% 2,127,555
26-11-06 GBX 1.725 -5.48% 1,199,780
  1. Stock Market
  2. Stocks
  3. GENF Stock